ConSynance Therapeutics received FDA Rare Pediatric Disease Designation for CSTI-500, an investigational drug for Prader-Willi Syndrome (PWS) treatment in children and adolescents.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.